Home News Dynavax down 11% premarket ahead of Ad Com review of Heplisav-B –...

Dynavax down 11% premarket ahead of Ad Com review of Heplisav-B – Dynavax Technologies Corporation (NASDAQ:DVAX)

21
0
SHARE


Dynavax (NASDAQ:DVAX) is now down 11% ahead of Friday’s Ad Com review of hepatitis B vaccine HEPLISAV-B as investors note the comments from the reviewers about the completeness of the safety data.

Previously: Dynavax up 21% ahead of Ad Com review of hepatitis B vaccine (July 26)



Source link

LEAVE A REPLY